Comparison of Prediction Models for Lynch Syndrome among Individuals with Colorectal Cancer

Journal of the National Cancer Institute

Volumn 108, Issue 2, 2016, Pages

  Kastrinos, Fay ^a   Ojha, Rohit P ^b   Leenen, Celine ^c   Alvero, Carmelita ^d   Mercado, Rowena C ^e   Balmaña, Judith ^f   Valenzuela, Irene ^f   Balaguer, Francesc ^g   Green, Roger ^h   Lindor, Noralane M ⁱ   Thibodeau, Stephen N ^j   Newcomb, Polly ^k   Win, Aung Ko ^l   Jenkins, Mark ^l   Buchanan, Daniel D ^l,q   Bertario, Lucio ^m   Sala, Paola ^m   Hampel, Heather ⁿ   Syngal, Sapna ^o,p   Steyerberg, Ewout W ^c  

^a NewYork Presbyterian Hospital   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

ⁱ MAYO CLINIC   (United States)

^j MAYO CLINIC   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ OHIO STATE UNIVERSITY   (United States)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; GENE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MLH1 GENE; MODEL; MSH2 GENE; MSH6 GENE; POPULATION RESEARCH; PREDICTION MODEL; PRIORITY JOURNAL; AREA UNDER THE CURVE; AUSTRALIA; CLINICAL TRIAL; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPLICATION; EUROPE; GENETICS; HETEROZYGOTE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NORTH AMERICA; PEDIGREE; PREDICTIVE VALUE; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AREA UNDER CURVE; AUSTRALIA; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA-BINDING PROTEINS; EUROPE; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; MUTL PROTEIN HOMOLOG 1; MUTS HOMOLOG 2 PROTEIN; NORTH AMERICA; NUCLEAR PROTEINS; PEDIGREE; PREDICTIVE VALUE OF TESTS; PREVALENCE; ROC CURVE;

EID: 84962617859     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv308     Document Type: Article

References (39)

1. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch Syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851-1860.
2. Jasperson KW, Tuohy TT, Neklason DW, Burt RW. Hereditary and Familial Colon Cancer. Gastroenterology. 2010;138(6):2044-2058.
3. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch Syndrome. Gastroenterology. 2009:137(5):1621-1627.
4. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer Risks Associated with Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome. JAMA. 2011;305(22):2304-2310.
5. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the Care of Individuals with an Inherited Predisposition to Lynch Syndrome: A Systematic Review. JAMA. 2006;296(12):1507-1517.
6. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424-425.
7. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23):1758-1762.
8. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
9. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch Syndrome. Genet Med. 2009;11(1):42-65.
10. van Lier MG, Leenen CH, Wagner A, et al. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch Syndrome. J Pathol. 2012;226(5):764-774.
11. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Guidelines for detection, prevention, and risk reduction. Genetic/Familial High-Risk Assessment: Colorectal Cancer. http:// www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf. Version 2.2014. Accessed June 17, 2014.
12. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch Syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2014;147(2):502-526.
13. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch Syndrome. JAMA. 2006;296(12):1479-1487.
14. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751-2763.
15. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM1, 2, 6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140(1):73-81.
16. Kastrinos F, Steyerberg EW, Balmaña J, et al. Comparison of the clinical prediction model PREMM1, 2, 6 and molecular testing for the systematic identification of Lynch Syndrome in colorectal cancer. Gut. 2013;62(2):272-279.
17. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2331-2343.
18. Ramsoekh D, van Leerdam ME, Wagner A, Kuipers EJ, Steyerberg EW. Mutation prediction models in Lynch Syndrome: evaluation in a clinical genetic setting. J Med Genet. 2009;46(11): 745-751.
19. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch Syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009;101(5):331-340.
20. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293(16):1986-1994.
21. Austin PC, Steyerberg EW. Graphical assessment of internal and external calibration of logistic regression models by using less smoothers. Stat Med. 2014;33(15):517-535.
22. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925-1931.
23. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.
24. Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol. 2010;37(1):31-38.
25. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138.
26. Localio AR, Goodman S. Beyond the usual prediction accuracy metrics: reporting results for clinical decision making. Ann Intern Med. 2012;157(4):294-295.
27. Khan O, Blanco A, Conrad P, et al. Performance of Lynch Syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011;106(10):1822-1827.
28. Balaguer F, Balmaña J, Castellví-Bel S, et al. Validation and extension of the PREMM1, 2 model in a population-based cohort of colorectal cancer patients. Gastroenterology. 2008;134(1):39-46.
29. Balmaña J, Balaguer F, Castellví-Bel S, et al. Comparison of predictive models, clinical criteria and molecular tumor screening for the identification of patients with Lynch Syndrome in a population-based cohort of colorectal cancer patients. J Med Genet. 2008;45(9):557-563.
30. Pouchet CJ, Wong N, Chong G, et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann Oncol. 2009;20(4):681-688.
31. Monzon JG, Cremin C, Armstrong L, et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer. 2010;126(4):930-939.
32. Tresallet C, Brouquet A, Julié C, et al. Evaluation of predictive models in daily practice for the identification of patients with Lynch Syndrome. Int J Cancer. 2012;130(6):1367-1377.
33. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch Syndrome. JAMA. 2006;296(12):1469-1478.
34. Win AK, MacInnis R, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013;50(12):785-793.
35. Leeflang MM, Bosuyt PM, Irwig L. Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J Clin Epidemiol. 2009;62(1):5-12.
36. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: A systematic review. Ann Intern Med. 2004;140(3):189-202.
37. Hampel H. Point: Justification for Lynch Syndrome screening among all patients with newly diagnosed colorectal cancer. JNCCN. 2010;8(5):597-601.
38. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129(2):415-421.
39. Moreira L, Balaguer F, Lindor NM, et al. Identification of Lynch Syndrome among patients with colorectal cancer. JAMA. 2012;308(15):1555-1565.